Compare Cadence Design Systems Inc (CDNS) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cadence Design Systems Inc vs TransMedics Group Inc — how do they compare? Cadence Design Systems Inc trades at $325.09 (market cap $90.20B), while TransMedics Group Inc trades at $87.2 (market cap $3.10B). The key difference: Cadence Design Systems Inc is far larger — about 29.1× TransMedics Group Inc's market cap, and Cadence Design Systems Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| CDNS | TMDX | |
|---|---|---|
Market Cap | $90.20B | $3.10B |
Sector | Technology | Technology |
52-Week High | $416.39 | $150.42 |
52-Week Low | $265.66 | $61.99 |
Enterprise Value | $91.41B | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cadence Design Systems (CDNS) trades at $326.75, down 1.55% amid a bearish technical signal, though strong fundamentals persist with Q2 2026 earnings beating estimates and AI-driven backlog hitting $8.1B. Revenue growth accelerated to 24% year-over-year, while profitability remains robust with 85.87% gross margins. The stock faces near-term pressure from technical indicators but maintains strong analyst support with an $415.11 consensus target.
The outlook remains positive given Cadence's leadership in semiconductor design software and exposure to AI growth, though high valuations (P/E 65.12) and technical bearishness pose risks. Investor sentiment is buoyed by record backlog and raised 2026 guidance, but competition and macroeconomic sensitivity could challenge further upside.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cadence Design Systems Inc
Cadence Design Systems is a provider of electronic design automation software, intellectual property, and system design and analysis products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Cadence offers a portfolio of design IP, as well as system design and analysis products, which enable system-level analysis and verification solutions. Cadence's comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers, alongside secular digitalization of various end markets, benefits EDA vendors like Cadence.
Read more on CDNS →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
